Capricor Therapeutics, Inc.(CAPR)
Financials

Historical Financials

	DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021	DEC 2020	DEC 2019	DEC 2018	DEC 2017	DEC 2016
Total Revenue	-	22,270,465	25,178,066	2,551,469	244,898	310,250	1,005,028	1,671,356	2,666,340	3,998,618
Gross Profit Margin (%)	-	-	-	-	-	-	-	-	-	-
R&D Expense	84,454,595	49,968,585	36,448,039	21,816,949	13,571,045	8,457,000	5,141,805	12,066,800	10,766,095	16,042,082

Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.

		DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021	DEC 2020	DEC 2019	DEC 2018	DEC 2017	DEC 2016
SG&A Expense
Total Operating Expenses
Operating Income or Loss
Operating Margin (%)
EBITDA
Interest Expense
Non-Operating Income/Expense
Income Before Tax
Income Tax Expense
Income from Continuing Ops.
Net Income
Net Profit Margin (%)
Basic EPS
Diluted EPS
Basic Average Shares
Diluted Average Shares

	DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021	DEC 2020	DEC 2019	DEC 2018	DEC 2017	DEC 2016
Total Revenue	-	22,270,465	25,178,066	2,551,469	244,898	310,250	1,005,028	1,671,356	2,666,340	3,998,618
Gross Profit Margin (%)	-	-	-	-	-	-	-	-	-	-
R&D Expense	84,454,595	49,968,585	36,448,039	21,816,949	13,571,045	8,457,000	5,141,805	12,066,800	10,766,095	16,042,082
SG&A Expense
Total Operating Expenses
Operating Income or Loss
Operating Margin (%)
EBITDA
Interest Expense
Non-Operating Income/Expense
Income Before Tax
Income Tax Expense
Income from Continuing Ops.
Net Income
Net Profit Margin (%)
Basic EPS
Diluted EPS
Basic Average Shares
Diluted Average Shares

All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.